Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase

Experimental Biology and Medicine

Volumn 233, Issue 11, 2008, Pages 1433-1440

  Tomoda, Chisato ^a,b   Moatamed, Farhad ^a   Naeim, Faramarz ^a   Hershman, Jerome M ^a   Sugawara, Masahiro ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cell cycle; Indomethacin; Medullary thyroid cancer; Prostaglandin; Sunitinib

Indexed keywords

INDOMETACIN; INDOMETACIN DERIVATIVE; INDOMETACIN ESTER; NAPROXEN; PROSTAGLANDIN; PROSTAGLANDIN E2; RETINOBLASTOMA PROTEIN; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; INDOLE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID CELL; THYROID MEDULLARY CARCINOMA; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION; GENETICS; MEDULLARY CARCINOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; GENE EXPRESSION; HUMANS; INDOLES; INDOMETHACIN; PHOSPHORYLATION; PYRROLES; RETINOBLASTOMA PROTEIN; S PHASE; THYROID NEOPLASMS;

EID: 58249091314     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0804-RM-127     Document Type: Article

References (23)

1. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006.
2. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2:632-642, 2004.
3. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10:4266s-4269s, 2004.
4. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, Heo DS, Kim KH. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 22:2089-2096, 2002.
5. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11:1999-2007, 2005.
6. Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A, Lausson S. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15- hydroxyprostaglandin dehydrogenase. Endocrinology 145:2561-2571, 2004.
7. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167, 2006.
8. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 81(1-2):14-30, 2006.
9. He H, Xia HH, Wang JD, Gu Q, Lin MC, Zou B, Lam SK, Chan AO, Yuen MF, Kung HF, Wong BC. Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. Cancer 106:1243-1249, 2006.
10. Kundu N, Walser TC, Ma X, Fulton AM. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54:981-987, 2005.
11. Ackerstaff E, Gimi B, Artemov D, Bhujwalla ZM. Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia 9:222-235, 2007.
12. Wang HM, Zhang GY. Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 11: 340-343, 2005.
13. de Groot DJ, van der Deen M, Le TK, Regeling A, de Jong S, de Vries EG. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer 97:1077-1083, 2007.
14. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896, 2007.
15. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006.
16. Nasu M, Sugawara M. Ethanol has thyrotropin-like activity in cultured porcine thyroid follicles. Endocrinology 132:155-160, 1993.
17. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995.
18. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 8:805-814, 1996.
19. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin- dependent kinases. Genes Dev 18:2699-2711, 2004.
20. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient highperformance liquid chromatographic analysis. Preliminary pharmaco- kinetics and effect of probenecid. J Chromatogr 616:271-282, 1994.
21. Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask DK. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog 46:857-864, 2007.
22. Matsunaga S, Asano T, Tsutsuda-Asano A, Fukunaga Y. Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 58:348-353, 2006.
23. Pan MR, Chang HC, Chuang LY, Hung WC. The nonsteroidal antiinflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (Maywood) 233:456-462, 2008.